CRDLCardiol Therapeutics Inc.同业对比
Cardiol Therapeutics Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRDL本股 | $102M#5 | — | — | — | — | — | — | — | — | — | -3.8%#2 | — |
| BNTX | $22.8B#1 | — | — | — | — | — | — | — | — | — | -13.5%#3 | — |
| CGEN | $193M#4 | 5.4x#2 | 1.9x#1 | 2.7x#1 | 161.1%#1 | 348.4%#1 | 43.1%#1 | 34.4%#2 | — | — | — | — |
| CKDXF | — | — | — | — | -80.0%#7 | 26.1%#3 | -623048.0%#8 | — | — | — | — | — |
| CLDWW | — | — | — | — | — | 10.1%#6 | -44977.8%#7 | -635.4%#7 | — | — | — | — |
| CLLS | — | — | — | — | 75.8%#2 | -83.9%#10 | -45.3%#2 | -89.1%#3 | — | — | -67.4%#6 | — |
| CPMV | — | — | — | — | — | 25.4%#5 | — | — | — | — | — | — |
| CYVNY | — | — | — | — | -80.0%#7 | 26.1%#3 | -623048.0%#8 | — | — | — | — | — |
| DBVT | $3.1B#2 | — | 21.1x#2 | 555.3x#2 | 35.8%#3 | -29.0%#8 | -2609.2%#4 | -98.9%#4 | — | — | -30.4%#5 | — |
| DBVTF | — | — | — | — | 35.8%#3 | -29.0%#8 | -2609.2%#4 | -98.9%#4 | — | — | — | — |
| ELUT | — | 0.8x#1 | — | — | -15.0%#5 | 198.9%#2 | -218.9%#3 | 339.0%#1 | -122.6%#1 | — | -16.6%#4 | — |
| ENTX | $542M#3 | 8.9x#3 | 74.6x#3 | 12903.2x#3 | -76.8%#6 | -19.9%#7 | -27450.0%#6 | -157.4%#6 | — | — | 10.6%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-05。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议